143 related articles for article (PubMed ID: 25211092)
41. Anti-CD20 antibody therapy for B-cell lymphomas.
Maloney DG
N Engl J Med; 2012 May; 366(21):2008-16. PubMed ID: 22621628
[No Abstract] [Full Text] [Related]
42. Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab.
Huang HC; Cheng AL; Lin CW; Kuo SH
Ann Hematol; 2013 Jul; 92(7):989-92. PubMed ID: 23242476
[No Abstract] [Full Text] [Related]
43. Acquired angioedema and marginal zone lymphoma.
Lam DH; Levy NB; Nickerson JM; Gruenberg DA; Lansigan F
J Clin Oncol; 2012 Jun; 30(16):e151-3. PubMed ID: 22508826
[No Abstract] [Full Text] [Related]
44. Multifocal mucosa-associated lymphoid tissue lymphoma associated with IgG4-related disease: a case report.
Oyama T; Takizawa J; Nakamura N; Aoki S; Aizawa Y; Abe H
Jpn J Ophthalmol; 2011 May; 55(3):304-306. PubMed ID: 21584726
[No Abstract] [Full Text] [Related]
45. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
Kyrtsonis MC; Siakantaris MP; Kalpadakis C; Dimopoulou MN; Vassilakopoulos TP; Kontopidou FN; Antoniou C; Korkolopoulou P; Panayiotidis P; Pangalis GA
Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
[TBL] [Abstract][Full Text] [Related]
46. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
47. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
48. Seronegative lyme neuroborreliosis in a patient using rituximab.
van Dop WA; Kersten MJ; de Wever B; Hovius JW
BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23417373
[TBL] [Abstract][Full Text] [Related]
49. Mucosa-associated lymphoid tissue (MALT) lymphoma of the esophagus.
Tsujii Y; Nishida T; Kato M; Inoue T; Yamamoto S; Hayashi Y; Akasaka T; Kondo J; Yamada T; Shinzaki S; Iijima H; Tsujii M; Takehara T
Dis Esophagus; 2013 Apr; 26(3):349-50. PubMed ID: 22882544
[No Abstract] [Full Text] [Related]
50. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
51. MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab.
Tektonidou MG
Lupus; 2010 Sep; 19(10):1243-5. PubMed ID: 20501524
[TBL] [Abstract][Full Text] [Related]
52. Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review.
Fernández-Guarino M; Ortiz-Romero PL; Fernández-Misa R; Montalbán C
Actas Dermosifiliogr; 2014 Jun; 105(5):438-45. PubMed ID: 23540593
[TBL] [Abstract][Full Text] [Related]
53. Expect the unexpected: primary breast MALT lymphoma.
Ghetu D; Membrez V; Bregy A; Vees HG; Hottelier D; Girardet C; Schneider N; Bieri S
Arch Gynecol Obstet; 2011 Nov; 284(5):1323-4. PubMed ID: 21800083
[No Abstract] [Full Text] [Related]
54. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
[TBL] [Abstract][Full Text] [Related]
55. [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)].
Tobinai K
Nihon Rinsho; 2002 Jan; 60(1):95-9. PubMed ID: 11808346
[TBL] [Abstract][Full Text] [Related]
56. Anti-CD20 antibody therapy for B-cell lymphomas.
Calcagno A; Rostagno R; Di Perri G
N Engl J Med; 2012 Aug; 367(9):877-8; author reply 878. PubMed ID: 22931340
[No Abstract] [Full Text] [Related]
57. Anti-CD20 antibody therapy for B-cell lymphomas.
El Fassi D; Hegedüs L; Nielsen CH
N Engl J Med; 2012 Aug; 367(9):877; author reply 878. PubMed ID: 22931339
[No Abstract] [Full Text] [Related]
58. Anti-CD20 antibody therapy for B-cell lymphomas.
Taylor RP; Lindorfer MA; Zent CS
N Engl J Med; 2012 Aug; 367(9):876-7; author reply 878. PubMed ID: 22931338
[No Abstract] [Full Text] [Related]
59. Selective loss of lymphoid component simulating myeloma in lymphoplasmacytic lymphoma treated with rituximab.
O'Connor SR; Rana SK
Br J Haematol; 2013 May; 161(4):460. PubMed ID: 23530469
[No Abstract] [Full Text] [Related]
60. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
